DAIICHI-SANKYO
Daiichi Sankyo Europe (hereafter, Daiichi Sankyo) today announced the launch of the Future of Heart Health in Europe: A Holistic Care Think Tank report. The report follows the first-of-its-kind holistic care Think Tank meeting, held earlier this year, which brought together influential representatives from various disciplines including clinicians, patient advocates, researchers, digital and media experts and policy specialists. Three strategic recommendations for incorporating a holistic approach to CV care in Europe arose from the meeting:
-
Improve lifelong support and education:
- Improving lifelong support and education from a young age to lay a strong foundation for sustained wellness; introducing programmes in the workplace that reward physical and mental well-being.
-
Increase interdisciplinary collaboration and communication:
- Assigning a patient case manager and embracing implementation of artificial intelligence to improve communication and coordination of interdisciplinary collaboration.
-
Changes in health policies across Europe:
- A holistic view of CV care should be included on political agendas at a European level. Policy changes will lead to better access to preventative care, support for the adoption of a healthy lifestyle, and removal of barriers to equitable healthcare.
Across Europe, CVD is responsible for the loss of 10,000 lives every day.3 However, cardiovascular conditions are largely preventable, and there is a growing emphasis on addressing the burden of CVD through behavioural changes and risk factor management. The holistic care Think Tank included experts with a focus on behavioural and physiological factors for CVD, such as diet, exercise, and mental health. These experts play a vital role in raising awareness of the various aspects of CVD and, together, can build a more holistic picture of a person’s health that goes beyond the view of the heart alone.
"Collaborating with a diverse array of stakeholders is paramount in adopting a truly holistic approach to heart health in Europe,” said Berk Kiran, Vice President, Commercial Operations Europe, Daiichi Sankyo Europe. “By harnessing the unique perspectives and expertise of individuals across disciplines, sectors, and backgrounds, we can help forge innovative solutions that address the challenges facing cardiovascular health today. Together, we can drive meaningful change and pave the way towards a healthier future for all."
“At a political level, I think that it's time to establish health promotion and cardiovascular prevention as a real priority,” said Professor Hélder Dores, Cardiologist, Portugal and member of the Think Tank. “In healthcare, I think that not only for cardiologists but for all the professionals, it’s important to amend how we’re determining an individual’s risk and to improve lifestyle, because as we know, the great majority of atherosclerotic events could be prevented if we address the underlying risk factors.”
The inaugural Think Tank meeting and report form part of Daiichi Sankyo’s ongoing heart health initiative: We Care for Every Heartbeat (WC4EHB).
For further information on holistic approaches to CV health and care in Europe and to read the full report please visit our WC4EHB website: https://wecareforeveryheartbeat.com/.
-ENDS-
About We Care for Every Heartbeat
At Daiichi Sankyo we care for every heartbeat. Our goal is to protect people from cardiovascular disease and help those who suffer from it, so they can enjoy every precious moment that life has to offer. Under the WC4EHB umbrella, Daiichi Sankyo regularly publishes informational blogs designed to improve health literacy and CVD care across Europe. We have conducted awareness surveys to uncover the public perception and attitude towards heart disease. We are working with external organisations, such as The Economist and the European Nutrition for Health Alliance (ENHA), to better understand the burden of CVD in Europe, and we partner with health specialists across a range of CV-relevant professions to advocate for greater collaboration and a holistic approach in Europe. We have made a long-term commitment to invest and work tirelessly to help patients and inspire positive change in CV care. For further information on WC4EHB and our activities, visit our website: https://wecareforeveryheartbeat.com/.
About CVD in Europe
CVD – a group of disorders affecting the heart and circulatory system, which can lead to heart attacks and strokes – is the primary cause of death in Europe, accounting for 45% of all deaths in the region and responsible for more than 10,000 lives lost every day.3,4,5,6 Furthermore, a large proportion of these deaths are premature – occurring before the age of 65 years – with CVD responsible for almost a quarter of premature deaths among men and nearly a fifth among women in Europe.7 Despite its high prevalence and burden, a lack of public awareness and gaps in understanding, especially of CVD risk factors, may be preventing those at risk from making positive lifestyle changes and adopting healthy habits to help reduce their CVD risk.8
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need.
For more information, please visit www.daiichisankyo.com
| References |
_____________________________ |
1 World Health Organization. Cardiovascular Diseases (CVDs) Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed May 2024. |
2 Luengo-Fernandez, R., et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023. 00: 1–16. |
3 Mach, F., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020. 41;(1): 111–188. |
4 European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Available at: https://ehnheart.org/wp-content/uploads/2023/07/CVD-Statistics.pdf. Last accessed May 2024. |
5 European Heart Network. CVD Statistics. Available at: https://ehnheart.org/about-cvd/the-burden-of-cvd/. Last accessed May 2024. |
6 Eurostat. Causes of death statistics. Available at: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics#Major_causes_of_death_in_the_EU_in_2020. Last accessed May 2024. |
7 European Heart Network. Fighting cardiovascular disease – a blueprint for EU action. Available at: https://www.escardio.org/static-file/Escardio/Advocacy/Documents/2020%20ESC-EHN-blueprint_digital%20edition.pdf. Last accessed May 2024. |
8 Daiichi Sankyo We Care for Every Heartbeat. European Survey Report of Cardiovascular Disease – Uncovering current public perceptions and attitudes towards cardiovascular disease. Available at: wecareforeveryheartbeat.com/wp-content/uploads/2023/08/European_Survey_Report_final_approved_Jul_2022.pdf. Last accessed May 2024. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520608896/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
Andersen Consulting udvider sin tilstedeværelse gennem samarbejde med Hilal Technology4.12.2025 23:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Hilal Technology for at styrke sine kompetencer inden for digital infrastruktur, cybersikkerhed og AI. Med tilstedeværelse i Bahrain, Saudi-Arabien, De Forenede Arabiske Emirater, Oman og Indien leverer Hilal Technology et komplet spektrum af digital infrastruktur og managed services inden for cloudcomputing, cybersikkerhed, enterprise ai og systemintegration. Deres ydelser omfatter cloudtjenester, sikkerheds- og netværksdrift, implementering af ERP og applikationer samt udvikling af generative ai-kapaciteter. Med et team på mere end 250 fagfolk servicerer firmaet en bred vifte af brancher, herunder den finansielle sektor, olie og gas, logistik og den offentlige sektor. "Transformation er mere end systemer; det handler om parathed, tillid og løbende samarbejde," udtaler Roshan George, direktør for Hilal Technology. "Vi er begejstrede for at samarbejde med Andersen Consulting og levere skalerbare løsninger, der matcher tempoet i den dig
Xsolla Integrates MVola as a Payment Method to Enable Instant, Card-Free Payments for Gamers in Madagascar’s Mobile-First Market4.12.2025 21:00:00 CET | Press release
MVola Integration Enhances Payment Accessibility And Supports The Growth Of Madagascar’s Thriving Mobile Gaming Ecosystem Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced that MVola, Madagascar’s number one digital wallet, is now available as a payment option for players across the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204268075/en/ Chris Hewish, President of Xsolla Madagascar is a fast-growing, mobile-first market of 32 million people, where digital wallets are the primary driver of daily transactions. MVola, recently licensed as a digital bank, has established itself as the leading wallet in the country, with over 10 million users and powering more than 1 billion transactions annually. By adding MVola as a payment method to its portfolio, Xsolla removes the friction of card payments, enabling players to pay seamlessly with a trus
Board Recognized as a Leader in the Gartner® Magic Quadrant™ for Financial Planning Software for Fourth Consecutive Year4.12.2025 18:14:00 CET | Press release
Fourth consecutive placement reflects Board’s Completeness of Vision and Ability to Execute Board, the leading Enterprise Planning Platform, today announced that it has been named a Leaderin the2025 Gartner® Magic Quadrant™ for Financial Planning Software. This marks the fourth consecutive year the company has been positioned in the Leaders quadrant. The Board Enterprise Planning Platform integrates planning processes across the enterprise, enabling strategic, financial, and operational planning with near-real-time analysis and data sharing. Board’s unified approach to planning has driven strong adoption across financial and operational planning in the manufacturing, consumer packaged goods (CPG) and retail sectors. “We are proud to once again be named a Leader in the Gartner Magic Quadrant for Financial Planning Software,” said Jeff Casale, CEO of Board. “To Board, this recognition reflects our continued commitment to helping organizations unify strategic, financial, and operational p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
